In patients with tumor AKT1 E17K mutation (0.77% frequency) treated with the pan-AKT inhibitor capivasertib, the ORR was 23% (all partial responses) and the 6-month PFS was 52%17. The gene discussed is AKT1; the disease is neoplasm.